BioCorRx Inc. (BICX) stock
Close on Oct 19, 2026Market cap $7.30MP/E –Yield –
BioCorRx Inc. grew revenue 10301.1% to $797.24K over fiscal 2025. At the latest close the market valued the company at $7.30M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $7.30M
- P/E ratio
- –
- Price to sales
- 9.16
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $797.24K
- Net income
- -$3.16M
- EPS, diluted
- -$0.15
- Book value per share
- -$0.42
- Diluted shares
- 29M
Trading
- Previous close
- $0.25
- Open
- $0.25
- Day's range
- $0.25 – $0.25
- Volume
- 0
- Average volume (20 days)
- 1,562
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BICX | S&P 500 | Difference | BICX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.9% | +0.6% | +10.2 pts | ||
| 3 months | -15.0% | +3.4% | −18.3 pts | ||
| Year to date | -14.1% | +13.3% | −27.4 pts | ||
| 1 year | -37.5% | +16.6% | −54.1 pts | ||
| 3 years | -84.5% | +86.4% | −170.9 pts | -46.3% | +23.1% |
| 5 years | -91.1% | +81.9% | −172.9 pts | -38.3% | +12.7% |
| 10 years | -93.8% | +318.9% | −412.6 pts | -24.2% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioCorRx filed with the SEC as exhibits to Form 8-K or 6-K
About BioCorRx
Services-Specialty Outpatient Facilities, NEC
BioCorRx Inc. develops and supplies medical solutions for substance use disorders and weight management. The company operates primarily through addiction treatment programs and clinical-stage pharmaceutical development. Its core offerings include the Beat Addiction Recovery Program, which combines proprietary cognitive behavioral therapy modules, mobile peer support, and physician-prescribed medication, and the UnCraveRx Weight Loss Program, which provides medication-assisted support alongside wellness coaching. Through its majority-owned pharmaceutical subsidiary, the company distributes Lucemyra for opioid withdrawal and conducts clinical research on BICX104, an implantable naltrexone pellet. BioCorRx provides its treatment programs and products to licensed healthcare providers, independent physicians, rehabilitation facilities, and commercial distributors.
Company profile, executives and historyBioCorRx stock: common questions
What is BioCorRx's stock price?
BICX closed at $0.25 on Oct 19, 2026, up 0.00% on the day.
What is BioCorRx's market cap?
BioCorRx was worth $7.30M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BICX's P/E ratio?
BioCorRx lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.15), so it has no meaningful P/E ratio.
How much revenue does BioCorRx make?
BioCorRx reported revenue of $797.24K for fiscal 2025, up 10301.1% from a year earlier.
Does BioCorRx pay a dividend?
No. BioCorRx has not paid a cash dividend over the last twelve months.
How has BICX stock performed over the past year?
Including dividends, BICX returned -37.5% over the past year, against +16.6% for the S&P 500.
Who are BioCorRx's competitors?
Companies most similar to BioCorRx by business, industry and size include BRTX, MGRX, EHSI, ATPC, HLYK.
See a number that looks wrong?